Bookmark and Share
BioAssay: AID 1545

Summary - Compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.

Congenital Disorders of Glycosylation (CDG) are autosomal recessive defects in the synthesis of N-linked oligosaccharide chains. CDG group I (CDG-I) defects are defined as those caused by mutations in genes encoding enzymes used for the synthesis and transfer of lipid linked oligosaccharide (LLO) to newly synthesized proteins in the lumen of the ER. The steps in this pathway and the genes more ..
_
   
 Tested Compounds
 Tested Compounds
All(2)
 
 
Probe(2)
 
 
Active(2)
 
 
 Tested Substances
 Tested Substances
All(2)
 
 
Probe(2)
 
 
Active(2)
 
 
AID: 1545
Data Source: Burnham Center for Chemical Genomics (BCCG-A142-PMI-Summary-Assay)
BioAssay Type: Summary, Candidate Probes/Leads with Supporting Evidence
Depositor Category: NIH Molecular Libraries Screening Center Network
BioAssay Version:
Deposit Date: 2009-03-12
Modify Date: 2010-12-29

Data Table ( Complete ):           View Active Data    View All Data
Target
BioActive Compounds: Chemical Probe: 2    Active: 2
Related Experiments
Show more
AIDNameTypeComment
1020Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary AssayScreeningdepositor-specified cross reference: Counter Screen for Glucose-6-Phosphate Dehydrogenase-based Primary Assay
1209HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.Confirmatorydepositor-specified cross reference: HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensi
1217uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-based Primary AssaysScreeningdepositor-specified cross reference: uHTS Identification of Diaphorase Inhibitors and Chemcical Oxidizers: Counter Screen for Diaphorase-
1220HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphateConfirmatorydepositor-specified cross reference: HTS identification of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensi
1535Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay.Confirmatorydepositor-specified cross reference: Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity ass
1536Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity assay using a high concentration of mannose 6-phosphate.Confirmatorydepositor-specified cross reference: Confirmation of compounds inhibiting phosphomannose isomerase (PMI) via a fluorescence intensity ass
1553Screening for Phosphomannose Isomerase inhibitors in cellular based assay using Hela cells.Otherdepositor-specified cross reference: Screening for Phosphomannose Isomerase inhibitors in cellular based assay using Hela cells.
1620Toxicity Screening of PMI Inhibitors in Hela cellsOtherdepositor-specified cross reference: Toxicity Screening of PMI Inhibitors in Hela cells
1655Counter screen SAR assay for PMM2 inhibitors via a fluorescence intensity assayConfirmatorydepositor-specified cross reference: Counter screen SAR assay for PMM2 inhibitors via a fluorescence intensity assay
1666SAR assay for compounds that inhibit PHOSPHO1Confirmatorydepositor-specified cross reference: SAR assay for compounds that inhibit PHOSPHO1
Description:
Data Source: Sanford-Burnham Center for Chemical Genomics (SBCCG)
Source Affiliation: Sanford-Burnham Medical Research Institute (SBMRI, San Diego, CA)
Network: NIH Molecular Libraries Screening Centers Network (MLSCN)
Grant Number: R03 MH082386-01
Assay Provider: Dr. Hudson H. Freeze, Sanford-Burnham Medical Research Institute, San Diego, CA

Congenital Disorders of Glycosylation (CDG) are autosomal recessive defects in the synthesis of N-linked oligosaccharide chains. CDG group I (CDG-I) defects are defined as those caused by mutations in genes encoding enzymes used for the synthesis and transfer of lipid linked oligosaccharide (LLO) to newly synthesized proteins in the lumen of the ER. The steps in this pathway and the genes encoding them are very similar from yeast to human. It requires 30-40 single gene products, each dependent on the previous step in the linear sequence to produce and transfer the LLO to protein. Therefore, mutations in any step may cause a type of CDG. There is considerable overlap in the clinical presentations between different types of CDG and a broad diversity within each type. The most common form of CDG, called Type Ia (CDG-Ia), is caused by defects in PMM2 (Man-6-P to Man-1-P), the gene that encodes phosphomannomutase. Mortality is 20% in the first 5 yrs, but then patients stabilize. Currently, there is no treatment for the CDG-Ia.

CDG-Ib patients, who are deficient in phosphomannose isomerase (PMI) catalyzing conversion of Man-6-P to Fru-6-P, are successfully treated with free mannose. Unfortunately, mannose therapy is not effective for CDG-Ia patients, most likely due to efficient Man-6-P consumption in the PMI reaction. It is believed that patients with Congenital Disorder of Glycosylation Type Ia (CDG-Ia) will benefit from dietary mannose if there is a simultaneous reduction of phosphomannose isomerase (PMI) activity. This would allow a modest intracellular accumulation of Man-6-P and drive metabolic flux into the glycosylation pathway using the residual PMM2 activity. It is assumed that a non-competitive inhibitor would work best in this setting; however, identification of chemical probes with diverse modes of action (MOA) would be advantageous for further characterization of PMI and PMM variants.

The purpose of this assay is to identify inhibitors of human PMI. This is accomplished by using a G6PD- NADPH-coupled assay. In the assay PMI activity is detected through conversion of its product, fructose-6-phosphate, to glucose-6-phosphate catalyzed by phosphoglucose isomerase (PGI) and subsequent oxidation of glucose-6-phosphate to 6-phosphogluconolactone concomitant with NADP-to-NADPH conversion catalyzed by glucose-6-phosphate dehydrogenase (G6PDH). The NADPH is then detected via a resazurin-diaphorase fluorogenic reaction.

AIDs 1020, 1209, 1217, 1220, 1535, 1536, 1553, 1620, 1655 and 1666 were carried out to select probe molecules SID57309177(ML096) and SID57287553(ML089).
Protocol
Please see pertinent AIDs: 1020, 1209, 1217, 1220, 1535, 1536, 1553, 1620, 1655, 1666.
Comment
Probe molecules are defined as the positives of this assay and assigned a score of 100.
Categorized Comment - additional comments and annotations
From MLP Probe Report:
Probe count: 2
MLP Probe ML# for probe 1: ML089
PubChem Substance ID (SID) for probe 1: 57287553
PubChem Compound ID (CID) for probe 1: 22416235
Probe type for probe 1: Inhibitor
IC50/EC50 (nM) for probe 1: 1300
Target for probe 1: PMI (gi: 16878311)
Anti-target for probe 1: PMM2
NCBI Book chapter link for probe 1: http://www.ncbi.nlm.nih.gov/books/NBK47345/ (ID: 2359032)
Grant number for probe 1: MH082386-01
MLP Probe ML# for probe 2: ML096
PubChem Substance ID (SID) for probe 2: 57309177
PubChem Compound ID (CID) for probe 2: 25199533
Probe type for probe 2: Inhibitor
IC50/EC50 (nM) for probe 2: 1070
Target for probe 2: PMI (gi: 16878311)
Anti-target for probe 2: PMM2
NCBI Book chapter link for probe 2: http://www.ncbi.nlm.nih.gov/books/NBK47350/ (ID: 2359426)
Grant number for probe 2: MH082386-01
NCBI Book chapter title for probe 1: Therapeutic Inhibitors of Phosphomannose Isomerase - Probe 1
NCBI Book chapter title for probe 2: Therapeutic Inhibitors of Phosphomannose Isomerase - Probe 2
Result Definitions
TIDNameDescriptionHistogramTypeUnit
OutcomeThe BioAssay activity outcomeOutcome
ScoreThe BioAssay activity ranking scoreInteger
1ML#ML# of the compoundString
Additional Information
Grant Number: R03 MH082386-01

Data Table (Concise)
Data Table ( Complete ):     View Active Data    View All Data
Classification
PageFrom: